Wegovy vs Mounjaro: The Complete Clinical Comparison
Is Wegovy Better Than Mounjaro: Understanding the Key Differences
When comparing Wegovy and Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. Mounjaro, containing tirzepatide, works as a dual agonist targeting both GIP and GLP-1 receptors, potentially offering a different approach to appetite regulation.
Both treatments are prescription-only medicines requiring clinical assessment before use. Neither medication is inherently "better" than the other - the choice depends on individual patient factors, medical history, and prescriber recommendation. At EverydayMeds, our clinical team can help determine which treatment aligns with your specific weight management goals and circumstances.
Pricing Comparison: Wegovy vs Mounjaro Investment
Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). Our bundle options provide convenience, such as the Intro Trio covering your first three months (0.25mg, 0.5mg, 1mg) for £299.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25.
Mounjaro follows a different dosing schedule with six available strengths from 2.5mg to 15mg. When considering "is Wegovy better than Mounjaro" from a cost perspective, the total investment varies based on your prescribed maintenance dose and treatment duration. Both treatments represent a significant commitment to your long-term health and weight management journey.
Clinical Evidence: Wegovy vs Mounjaro Trial Data
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events with Wegovy treatment.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, showing significant weight loss outcomes in its own patient populations. However, direct head-to-head comparisons between the treatments aren't available due to different trial designs, patient populations, and endpoints.
How Wegovy Works for Weight Management
Wegovy functions as a GLP-1 receptor agonist, closely mimicking the incretin hormone your intestines naturally produce after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety. The medication promotes a feeling of fullness after smaller meals, helping patients naturally reduce their caloric intake. Additionally, Wegovy may reduce food cravings and slow gastric emptying, extending the sensation of satisfaction after eating. This comprehensive approach to appetite regulation supports sustainable weight management when combined with lifestyle modifications.
Streamlined Ordering Process for Both Treatments
EverydayMeds offers the same efficient process whether you're prescribed Wegovy or Mounjaro. Begin with our 3-minute online clinical assessment, providing essential medical history and current health information. Our prescribers review your assessment within 3 working days (or 24 hours with express service) to determine treatment suitability. Once approved, your prescription is dispensed from our GPhC-registered pharmacy (#9012878) and dispatched via temperature-controlled next-day delivery. This cold-chain process ensures your medication maintains optimal effectiveness from our pharmacy to your door. Our clinical team remains available for ongoing support throughout your treatment journey.
Storage and Practical Considerations
Wegovy offers a practical storage advantage when comparing "is Wegovy better than Mounjaro" for lifestyle flexibility. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. Both medications require refrigerated storage at 2-8°C before first use and utilise pre-filled injection pens for convenience. Wegovy's FlexTouch pen design provides easy dose selection and injection. The mandatory dose escalation schedule for Wegovy spans 16 weeks, gradually increasing from 0.25mg to the maintenance 2.4mg dose to minimise side effects. This structured approach helps your body adjust to the medication progressively.
Mechanism Comparison: Single vs Dual Receptor Targeting
The question "is Wegovy better than Mounjaro" often centres on their distinct mechanisms of action. Wegovy's focused GLP-1 receptor agonism provides established, well-understood appetite regulation with extensive real-world experience since its UK approval. This single-target approach has demonstrated consistent efficacy across diverse patient populations in the STEP trial programme.
Mounjaro's dual GIP and GLP-1 receptor agonism represents a newer approach to weight management, potentially offering different metabolic benefits through its additional GIP pathway activation. Neither mechanism is superior - they simply represent different therapeutic strategies that may suit different patients based on their individual physiology and medical circumstances.
Making Your Choice: Expert Prescriber Guidance
Rather than asking "is Wegovy better than Mounjaro," the more relevant question is which treatment suits your specific needs, medical history, and lifestyle. Our prescribers consider factors including your BMI, existing health conditions, previous weight loss attempts, and personal preferences when recommending treatment. Both medications are available from EverydayMeds with the same professional oversight and support. Use discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout for the best pricing. Start your clinical assessment today at https://everydaymeds.co.uk/collections/weight-loss to determine which treatment path aligns with your weight management goals. Our clinical team remains committed to supporting your journey with evidence-based prescription-only medicines and ongoing professional guidance.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
